Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.35 |
| ▸ | HTR2A | P28223 | 4/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | HTR2B | P41595 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9938061 | 0.85 | MPO (0.40) | IDO1AGXTMPOLOXL2SLC6A4 | |
| SCHEMBL2425944 | 0.78 | GAA (0.46) | SLC6A4HTR2ASLC6A2SLC6A3HTR2C | |
| Hydrochloric Acid SCHEMBL2526731 | 0.77 | SLC6A2 (0.44) | IDO1AGXTSLC6A4HTR2ASLC6A2 | |
| SCHEMBL3711714 | 0.76 | IDO1 (0.42) | IDO1AGXTMPOLOXL2SLC6A4 | |
| SCHEMBL9939458 | 0.75 | PNMT (0.43) | IDO1LOXL2TAAR1 | |
| SCHEMBL16634552 | 0.74 | ALDH1A1 (0.48) | IDO1AGXTSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL3288376 | 0.73 | MAPT (0.46) | IDO1AGXTMPO | |
| SCHEMBL15819560 | 0.73 | HTR1A (0.43) | IDO1AGXTMPOSLC6A4HTR2A | |
| SCHEMBL27726752 | 0.73 | IDO1 (0.37) | IDO1AGXTMPOSLC6A4HTR2A | |
| SCHEMBL1398079 | 0.73 | ALDH1A1 (0.46) | IDO1AGXTMPOLOXL2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651917-A1 | DIMERIC IAP INHIBITORS | Novartis AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2013-10-10 | — | — | US | disclosed |
| WO-2012080260-A1 | DIMERIC IAP INHIBITORS | NOVARTIS AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130266590-A1 | DIMERIC IAP INHIBITORS | XIAP, BIRC5, BIRC2 | IDO1 2449/4885AGXT 3429/4885MPO 2336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.